Latest Regulatory Engagement News

Critical Minerals Group’s Pre-Feasibility Study for its Lindfield Vanadium Project delivers a robust $821 million pre-tax NPV and 26.6% IRR, setting the stage for a Definitive Feasibility Study and potential final investment decision in 2027.

CGN Resources has bolstered its position in the Leonora gold district by acquiring the 142 km² Desdemona Project, expanding its landholding to 386 km². The company has initiated its first reverse circulation drilling program at Christmas Well targeting multiple high-priority gold prospects.

Neurotech International has secured FDA clearance for its Investigational New Drug application for NTI164, enabling clinical development in the US and advancing its global registration and commercialisation plans.

CLINUVEL Pharmaceuticals secures Canadian marketing approval for SCENESSE®, expanding access to the only approved systemic photoprotective treatment for erythropoietic protoporphyria (EPP).

Imugene has secured $11.12 million through a placement to advance its allogeneic CAR-T therapy azer-cel after early clinical data showed complete responses in BTKi-resistant lymphoma patients.

Noxopharm has taken a key regulatory step by requesting a pre-IND meeting with the US FDA for its autoimmune drug candidate SOF-SKN, aiming to smooth the path for clinical development and boost its commercial appeal.

NobleOak Life has obtained in-principle ex gratia relief from Victorian insurance duty on premiums paid in early 2025, potentially reducing its previously provisioned $6.5 million liability.

Ausgold Limited is accelerating development at its Katanning Gold Project, with siteworks underway, modular accommodation nearing completion, and key engineering and power contracts signed to support a final investment decision by end-2026 and first gold production in mid-2028.

Taiko Critical Minerals secures a conditional NZ$20 million government funding offer to co-finance a NZ$40 million wet separation plant at Barrytown, boosting project credibility and accelerating development plans.

PEXA faces a proposed 20% cut in regulated ELNO service fees, risking a $70 million revenue reduction over a year. The company urges a phased approach to mitigate business impact as IPART opens public consultation.

Prodigy Gold is progressing key regulatory approvals to restart mining at its Old Pirate gold mine, supported by encouraging ore sorting testwork that significantly upgrades gold grades and promises operational efficiencies.

AdAlta has met a key US$1 million milestone payment under its China collaboration, gaining critical clinical data and securing proprietary materials for Australian manufacturing of its lead CAR-T therapy BZDS1901.